Shape-shifting cyclic peptides
Kitsune Bio
Using structural chemistry to create cyclic peptides that cross into cells, adapt to environments, and bind dynamic targets
advantage 1
Shape-Shifting
Our cyclic peptides spontaneously cycle through over 1,000 structural isomers, to reach the most effective conformation for the task.
Advantage 2
Cell-Penetrant
By leveraging structural diversity, our cyclic peptides can adopt conformations that allow them to access intracellular targets.
Advantage 3
Target Adaptive
Dynamic shape-shifting increases binding potential to traditionally undruggable targets.
Advantage 4
Design Friendly
Our platform allows for spontaneous conformation change in almost any cyclic peptide backbone.
An asset-forward platform based on Shape-Shifting Cyclic Peptides (SSCP's), with advantages over small molecules, biologics, and other cyclic peptide platforms through structural adaptability.
Current operations are centered on internal asset optimization and indication prioritization. Contact us for more details on collaboration, services, and licensing.
Team
CEO
Makenna Morck, PhD
Biochemistry at Stanford University. Over 3 years as a biotech and pharmaceutical consultant. Executive experience at Radar Therapeutics.
COO
Alec Santiago, PhD
Molecular Genetics at MD Anderson Cancer Center. Previously Executive Director of Enventure and Co-Founder of Van Heron Labs. Named 'Top 100 Latino Founders' in 2022.
CSO
Michael Stowell, PhD
Innovator of the SSCP technology, Michael is a neurobiologist and biochemist with decades of experience, 55 publications, and over 7,000 citations.
Contact Us
We are currently open to exploring collaborations in the cyclic peptide space, reviving assets that have failed at penetrance or binding, or discussing other strategic projects.
© Kitsune Biotherapeutics. All rights reserved.
Thank you
Accumsan orci faucibus id eu lorem semper. Eu ac iaculis ac nunc nisi lorem vulputate lorem neque cubilia ac in adipiscing in curae lobortis tortor primis integer massa consequat.